Drugs / HFB200603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05789069 | May 2023 → Dec 2026 expected | colorectal cancer, gastric cancer, melanoma, non-small cell lung carcinoma +1 | HiFiBiO Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-06 | HiFiBiO Therapeutics | Regulatory HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 hifibio.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-06 | HiFiBiO Therapeutics | HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 hifibio.com ↗ |
| 2022-11-18 | HiFiBiO Therapeutics | HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors hifibio.com ↗ |
| 2022-04-18 | HiFiBiO Therapeutics | HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment hifibio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFB200603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05789069 ↗ |
| Route | Intravenous | “Participants will be administered HFB200603 at dose levels 1-4 as an intravenous infusion” NCT05789069 ↗ |
| Target | BTLA | “Anti-BTLA Antibody” NCT05789069 ↗ |